Best Available Copy

Complete If Known Substitute for form 1449A/PT Application Number 10/618,977 July 14, 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANTES INFORMATION DISCLOS Group Art Unit Brian Bates, et al. 1762 Thomas Sweet (use as many sheets as nacessary) Attorney Docket Number PA-PA-\$335-RFB (8627/742) of 2

	Foreign Patent Document						Pages, Columna, Lines,	
Examiner Initials*	Cite No.	Office 3		Code ⁵ wn)	Name of Patentee or Applicant of Cited Occument	Date of Publication of Cited Occurrent MM-DD-YYYY	White Relevant Passages of Relevant Figures Appear	.т •
7TJS/	C21	DE	4446694		Schering AG	12/1994		
1	C22	DE	69403966		Burt et al.	02/05/1998		<u> </u>
	C23	DE	10244847.7			11/1/1/2002		<u> </u>
	C24	EP	07()6376		Angiotech Pharm, Inc.	07/19/1993	111	
	C25	EP	08:29238	B1	Gray Lary Banning	09/13/2000	1 y 14 1 1 1 2 2 2	<u> </u>
	C26	WC.	92/11890	A1	Michael Dror	07/23/1992	3	ļ
	C27	wc.	92/15282		Keith March	09/17/1992		
	C28	wc.	94/07/184		Shively it äl.	04/14/1994		<u> </u>
	C29	wc	94/23787	A1	David Rammler	10/27/1994		_
	C30	wc.	95/03795		Government of USA	07/29/1993	02/1995	ļ
	C31	WO	96/20718	A2	Charles Hart	07/11/1996		ļ
	C32	wc,	96/38183		Ramot Univ. Israel	05/1995	12/1996	
	C33	WC	97/26862		Schering AG.	01/1997		 -
	C34	WCi	98/24427		Angiotech Pharm Hnc.	12/1994	06/1998	<u> </u>
	C35	WCi	98/43618		Neorxcorp	03/1907	10/1998	
	C36	wo	99/62510		Angiotech Pharmiling.	06/1998	12/1999	↓
	C37	WO	0006152		Novopharm Blottich	07/4998	02/2000	1
	C38	WC	00/10552		Global Vascular Concepts	08/1996	03/2000	
	C39	WC	00/44414	A1	You-Ling Fan	08/03/2000		
	C40	WO	00/45744		Dachuan Yang	08/10/2000		<u> </u>
	C41	WO	02/066092		Levesque et al.	08/29/2002	N	
	C42	WO	03/026718	A1	Anthony Ragheb	04/03/2003		
V	C43	WO	03/043166		Gaedicke e al.	06/12/2003		
/TJS/	C44	WO	2004/028610	A2	Ulrich Speck et e	04/08/2004		

EXAMINER

/Thomas J Sweet/ (04/11/2007)

Burden Hour Statement: This form is estimated to take 2.0 hours to complet cer, U.S. Fatent and Trademark Office, Washington on the amount of time you are required to complete this form should be sent and DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS AND nto mation Cft omn issioner for Patents, Washington, DC 20231.

8/11/1U

SIGNATURE *EXAMINER: Initial if elerence considered, whether or not citation is in confirm not considered. Include to by of this form with next communication to applicant

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Desument code (WIPO Standard ST.5). ⁴ For lapanese patent documents, the indication of the number of the patent document. ⁵ Kind of document by the appropriate symbols as it possible. ⁶ Applicant is to place a check mark here if English language Translation in the standard process. Emperor must precede the serial consunder WIPO Standard \$7.16 if